08/04/2026
📊 Investment Proposal
Safwat Al Dawa Global
Building a Regional Healthcare Hub in North Africa & the Sahel
1. Executive Summary
Safwat Al Dawa Global is a Libya-based healthcare company focused on pharmaceutical distribution, medical infrastructure, and diagnostic services.
We are seeking strategic international partners to co-develop:
A modern hospital in Tripoli
Diagnostic and imaging centers
Pharmaceutical supply chain operations
Expansion into underserved Sahel markets
👉 Our goal is to become a regional healthcare leader connecting Africa, Europe, and the Middle East.
2. Market Opportunity
📍 Libya
Population: ~7 million
Heavy reliance on imported pharmaceuticals
Growing demand for private healthcare
🌍 Sahel Region (Target Expansion)
Population: 100M+ (Niger, Chad, Mali, Sudan )
Severe shortage of:
Hospitals
Diagnostics
Medical supply chains
👉 High demand + low competition = strong investment potential
3. Project Components
🏥 1. Tripoli Medical Hub
150–250 bed hospital
Advanced diagnostic center (MRI, CT, Labs)
Specialized clinics
💊 2. Pharmaceutical Distribution Platform
Import & distribution of medicines
Cold chain logistics
Exclusive agency partnerships
🌍 3. Regional Expansion
Establish branches in:
Niger
Chad
Mali
Launch diagnostic centers as entry points
4. Investment Requirement
💰 Total Estimated Investment:
USD 80M – 120M
Component
Investment
Hospital
$40M – $60M
Diagnostic Centers
$10M – $20M
Pharma Distribution
$15M – $25M
Regional Expansion
$15M
5. Partnership Models
We offer flexible structures:
🤝 Option 1: Joint Venture
Shared ownership (40%–60%)
Profit sharing
🤝 Option 2: Strategic Partnership
Technology + supply agreements
Revenue sharing
🤝 Option 3: Equity Investment
Direct investment in Safwat Al Dawa
Long-term ROI
6. Competitive Advantages
✅ Strategic location (Gateway to Africa)
✅ Strong local network & government access
✅ High unmet demand
✅ Multi-sector model (Healthcare + Pharma + Diagnostics)
✅ First-mover advantage in Sahel region
7. Financial Projections (5 Years)
Year
Revenue
EBITDA
Year 1
$10M
-
Year 2
$25M
10%
Year 3
$50M
18%
Year 4
$85M
22%
Year 5
$120M
25%
👉 Break-even expected in Year 2–3
8. Exit Strategy
IPO (Long-term)
Strategic buyout
Dividend-based returns
9. Partnership Opportunities
We are looking for:
Pharmaceutical manufacturers
Medical equipment companies
Hospital operators
Investment funds
10. Call to Action
We invite international partners to join us in transforming healthcare in Libya and the Sahel region.
📩 Contact us to explore:
Detailed feasibility study
Site visits
Partnership structuring
